Characterization of BRCA1/2 Variants in Various Tumor Types of Vietnamese Patients Using Next-Generation Sequencing
By
Hong-Thanh Nguyen
Minh-Duc Vu
Dinh-Dung Nguyen
Phuong-Nhung Dinh
Van-Quy Hoang
Linh-Trang Ngoc Bui
Dinh-Tuan Nguyen
Phuoc-Huy Do
Thi-Oanh Tong
Van-Hung Nguyen
Thu-Huong Thi Han
Sy-Tung Ha
Huy-Duong Do
Thanh-Ha Thi Ly
Viet-Nhan Nguyen
July 17, 2026
Clinical Scorecard: Characterization of BRCA1/2 Variants in Various Tumor Types of Vietnamese Patients Using Next-Generation Sequencing
At a Glance
Category Detail
Condition BRCA1/2 mutations in hereditary cancers Key Mechanisms Disruption of DNA repair mechanisms leading to genomic instability and carcinogenesis. Target Population Vietnamese patients with breast, ovarian, prostate, and pancreatic cancers. Care Setting Oncology hospitals in Vietnam utilizing next-generation sequencing.
Key Highlights
BRCA1/2 mutations are significant risk factors for hereditary breast, ovarian, and prostate cancers. Next-generation sequencing is used to identify BRCA1/2 mutations in Vietnamese patients. PARP inhibitors show efficacy in treating BRCA-mutated cancers. Routine BRCA1/2 testing is recommended for personalized treatment strategies. There is a knowledge gap regarding BRCA1/2 mutation prevalence in the Vietnamese population. Guideline-Based Recommendations
Diagnosis
Follow NCCN Guidelines for Genetic/Familial High-Risk Assessment for breast, ovarian, pancreatic, and prostate cancers. Management
Consider PARP inhibitors for patients with BRCA-mutated cancers. Monitoring & Follow-up
Regularly assess BRCA1/2 mutation status in patients with relevant cancer types. Risks
Increased genomic instability and risk of carcinogenesis associated with BRCA1/2 mutations. Patient & Prescribing Data
Patients diagnosed with triple-negative breast cancer, high-grade serous ovarian cancer, prostate cancer, or pancreatic cancer.
BRCA1/2 status is a key determinant in selecting targeted therapies.
Clinical Best Practices
Implement routine BRCA1/2 testing for eligible cancer patients. Utilize next-generation sequencing for comprehensive mutation analysis. Provide genetic counseling based on BRCA1/2 testing results. Related Resources & Content
